Overview

Despite advances in reperfusion with primary stenting, progress in STEMI outcomes has stalled over the past 20 years.  With 90% of coronary blood flow in the capillaries, the answer might be in the microvasculature.(1)  TherOx SSO2 Therapy is the first FDA approved therapy shown to significantly reduce infarct size in STEMI patients.(2)  Pre-clinical studies showed that SSO2 improves microvascular flow, which is strongly associated with mortality and hospitalization for HF within 1 year.(3),(4)   

Learn about the mechanism and data around SSO2 Therapy for STEMI patients.

(1) Kaul S, et al. Circulation. 2004;109:146–149.

(2)  SSO2 Therapy is indicated for use in anterior STEMI patients immediately following primary PCI completed within 6 hours of symptoms onset. 

(3) Spears, et al. J Invas Cardiol 2002;14:160-6.

(4) DeWaha, et al. European Heart Journal (2017) 38, 3502–3510.

To find out more about SSO2 Therapy, visit: https://info.zoll.com/contact-a-product-expert-for-therox-sso2-therapy-zoll